In This Article:
GLENVIEW, Ill., April 28, 2025--(BUSINESS WIRE)--Asahi Kasei Bioprocess America, Inc. (AKBA), a leader in advanced filtration and fluid management solutions for the biopharmaceutical industry, has been recognized with the Best Technologies Innovation Award at INTERPHEX 2025. This recognition was for AKBA’s THESYS® Cleavage & Deprotection (C&D) and Tangential Flow Filtration (TFF) unit, a groundbreaking system redefining oligonucleotide manufacturing efficiency.
Oligonucleotides (oligos) are short strands of synthetic DNA or RNA crucial in developing advanced therapies, including those for genetic disorders and cancer.
AKBA stood out for creating a novel solution for oligo manufacturing that integrates two traditionally separate unit operations, C&D and UF/DF, into a single streamlined system. Combining them into an automated process maximizes efficiency, which is critical for biomanufacturers that want to increase their oligo throughput and scale production.
"Asahi Kasei Bioprocess has been a driving force in advancing oligo manufacturing for years, and innovations like this THESYS unit help develop the next generation of therapeutics," said Chris Rombach, President of Asahi Kasei Bioprocess America. "This award validates our commitment to advancing the field and reflects the value we bring to customers through forward-thinking technologies."
INTERPHEX is one of the premier events for the pharmaceutical and biotechnology industries and showcases the latest in drug manufacturing innovation. This year’s award highlights technologies that push boundaries and have the potential to change the way pharmaceutical and biotech companies operate.
The THESYS C&D/TFF unit eliminates the need for separate equipment, saving valuable lab floor space. It also enables quick, sequential processing before purification. The standard system includes advanced controls, an ergonomic design, and an integrated tank.
Learn more about the benefits and cutting-edge features of the award-winning THESYS C&D/TFF unit.
About Asahi Kasei Bioprocess
The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances worldwide. Built with pride, built with quality, built to exceed expectations. "Built for You." For more information, please visit https://fluidmgmt.ak-bio.com.